Biodesix
Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in blood-based tests for lung cancer. The company offers a range of diagnostic tests, including the Nodify XL2 and Nodify CDT tests, designed to help physicians assess the risk of malignancy in patients with suspicious lung nodules. Its GeneStrat tumor profiling and VeriStrat immune profiling tests facilitate timely treatment decisions for oncologists. Biodesix employs a proprietary mass spectrometry-based discovery platform to develop multivariate protein diagnostics, with VeriStrat being one of its first products that assists in treatment selection for advanced lung cancer. The company also collaborates with biopharmaceutical firms to provide services for diagnostic research, clinical trial testing, and the development of companion diagnostics. Tests are processed in a CLIA-certified laboratory, with results typically reported within 72 hours. Through its innovative diagnostic solutions, Biodesix aims to enhance disease detection, diagnosis, and treatment guidance, ultimately improving patient outcomes.
Oncimmune (USA) LLC, founded in 2006 and a subsidiary of Oncimmune LTD in Nottingham, England, specializes in early cancer detection through innovative autoantibody assay technologies. The company aims to create tests capable of identifying over 90 percent of solid-tumor cancers, which account for 70 percent of all cancer cases, including lung, breast, colorectal, prostate, stomach, pancreatic, and ovarian cancers. Ongoing research and development efforts are led by Dr. John Robertson, who pioneered the underlying biological technology. Oncimmune operates a CLIA-certified laboratory in metro Kansas City, providing essential diagnostic services. The company also holds a significant portfolio of patents related to its diagnostic technologies, underscoring its commitment to advancing personalized immunodiagnostics for cancer screening and detection.
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.